99mTc-MIP-1404 SPECT/CT Companion Diagnostic for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.99mTc-MIP-1404 SPECT imaging is feasible for staging and assessing eligibility for prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT). Pre-treatment uptake intensity predicts response to 177Lu-PSMA RPT in metastatic castration-resistant prostate cancer.
Area Of Science
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background
- Metastatic castration-resistant prostate cancer (mCRPC) requires effective staging and treatment selection.
- Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) shows promise for mCRPC.
- Accurate assessment of eligibility for PSMA-targeted RPT is crucial.
Purpose Of The Study
- To evaluate the feasibility, diagnostic performance, and predictive value of 99mTc-MIP-1404 SPECT.
- To assess its utility in staging and determining eligibility for PSMA-targeted RPT in mCRPC patients.
- To correlate imaging findings with treatment response and survival outcomes.
Main Methods
- Retrospective analysis of 46 patients with mCRPC undergoing 99mTc-MIP-1404 SPECT/CT.
- Assessment of image quality, presence, and localization of pathologic uptake.
- Comparison with post-therapeutic 177Lu-PSMA scans and evaluation of uptake intensity's predictive significance.
Main Results
- 99mTc-MIP-1404 scans demonstrated excellent image quality (98%) and near-perfect agreement with 177Lu-PSMA scans (κ = 0.957).
- Uptake intensity higher than liver uptake predicted treatment response and prolonged progression-free survival.
- Higher 99mTc-MIP-1404 uptake was an independent predictor of treatment response in multivariable analysis.
Conclusions
- 99mTc-MIP-1404 SPECT/CT is a feasible and accurate imaging tool for staging mCRPC and assessing eligibility for PSMA-targeted RPT.
- Pre-treatment uptake intensity on 99mTc-MIP-1404 scans is a significant predictor of response to 177Lu-PSMA RPT.
- This imaging modality can aid in patient selection for advanced prostate cancer therapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Radioactive Tracer: PET involves using biologically active molecules labeled with radioactive isotopes, known as tracers or radiotracers. The...
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...